Breaking News Instant updates and real-time market news.

BNTX

BioNTech

$16.32

-0.19 (-1.15%)

08:48
11/04/19
11/04
08:48
11/04/19
08:48

BioNTech initiated with a Buy at Canaccord

Canaccord analyst Arlinda Lee initiated coverage of BioNTech with a Buy rating as the company seeks to deliver immunotherapy personalized for each patient's immune system, genetic background, and tumor characteristics. The company has eight clinical drug candidates, six partnerships, and the potential to generate many more therapeutic candidates. Lee has a $22 price target on BioNTech shares.

BNTX BioNTech
$16.32

-0.19 (-1.15%)

11/04/19
UBSW
11/04/19
INITIATION
Target $21
UBSW
Buy
BioNTech initiated with a Buy at UBS
UBS analyst Andrew Ang initiated coverage of BioNTech with a Buy rating and $21 price target. The analyst believes that the company can generate about $500M in risk-adjusted sales with BNT111 and about $730M with BNT122 after seeing "encouraging monotherapy and combo clinical efficacy and safety results for BNT111" in tough to treat checkpoint inhibitor failure patients as well as in BioNTech's first-gen iNeST program, BNT121 also in CPI failures. Further data readouts and details of the company's early stage non-mRNA platform could yield additional upside, Ang says in his research note.
11/04/19
LEER
11/04/19
INITIATION
Target $20
LEER
Outperform
BioNTech initiated with an Outperform at SVB Leerink
SVB Leerink analyst Daina Graybosch initiated coverage of BioNTech with an Outperform rating and $20 price target.
11/04/19
BREN
11/04/19
INITIATION
Target $25
BREN
Buy
BioNTech initiated with a Buy at Berenberg
Berenberg analyst Shanshan Xu initiated coverage of BioNTech with a Buy rating and $25 price target.
11/04/19
JPMS
11/04/19
INITIATION
Target $23
JPMS
Overweight
BioNTech initiated with an Overweight at JPMorgan
JPMorgan analyst Cory Kasimov initiated coverage of BioNTech with an Overweight rating and $23 price target. The company is taking an immuno-oncology approach to attack cancer and using multiple tools to address the heterogeneous nature of tumor biology, Kasimov tells investors in a research note. He sees a "well-defined catalyst calendar" with BioNTech having at least five programs reading out over the course of 2020.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$342.06

6.21 (1.85%)

15:35
12/09/19
12/09
15:35
12/09/19
15:35
Hot Stocks
Senator Markey says Tesla Autopilot 'can't be allowed' to replace drivers »

U.S. Senator Ed Markey, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 07

    Jan

CASY

Casey's General Stores

$175.80

(0.00%)

15:34
12/09/19
12/09
15:34
12/09/19
15:34
Options
Caseys General Stores options imply 8.0% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

MSFT

Microsoft

$151.60

-0.17 (-0.11%)

15:33
12/09/19
12/09
15:33
12/09/19
15:33
Hot Stocks
Microsoft to shut down Wunderlist on May 6, 2020 »

Microsoft said in a blog…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AQST

Aquestive Therapeutics

$7.89

-0.13 (-1.62%)

15:25
12/09/19
12/09
15:25
12/09/19
15:25
Conference/Events
Aquestive Therapeutics holds analyst & investor event w/conference call hookup »

Management and Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

PTLA

Portola Pharmaceuticals

$28.48

-0.74 (-2.53%)

15:24
12/09/19
12/09
15:24
12/09/19
15:24
Hot Stocks
Portola presents new interim Phase 2a data from study of cerdulatinib »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARQL

ArQule

$19.72

10.045 (103.88%)

15:21
12/09/19
12/09
15:21
12/09/19
15:21
Downgrade
ArQule rating change  »

ArQule downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

TOL

Toll Brothers

$41.50

0.62 (1.52%)

15:19
12/09/19
12/09
15:19
12/09/19
15:19
Options
Toll Brothers options imply 8.6% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
12/09/19
12/09
15:17
12/09/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
12/09/19
12/09
15:16
12/09/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$33.53

-0.06 (-0.18%)

15:15
12/09/19
12/09
15:15
12/09/19
15:15
Options
Dish put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGNX

MacroGenics

$9.87

0.19 (1.96%)

15:09
12/09/19
12/09
15:09
12/09/19
15:09
Hot Stocks
MacroGenics announces updated results from Phase 1/2 study of flotetuzumab »

MacroGenics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MDB

MongoDB

$131.13

-0.09 (-0.07%)

15:04
12/09/19
12/09
15:04
12/09/19
15:04
Options
MongoDB options imply 14.8% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 18

    Dec

IMGN

ImmunoGen

$4.06

0.195 (5.05%)

15:03
12/09/19
12/09
15:03
12/09/19
15:03
Hot Stocks
ImmunoGen presents updated findings from Phase 1 study of IMGN632 at ASH meeting »

ImmunoGen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
12/09/19
12/09
15:00
12/09/19
15:00
General news
U.S.-China trade/tariff uncertainty is still present »

U.S.-China trade/tariff…

NVS

Novartis

$92.68

0.6 (0.65%)

14:53
12/09/19
12/09
14:53
12/09/19
14:53
Hot Stocks
Novartis says Kymriah demonstrates consistent efficacy, safety outcomes »

Novartis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

GILD

Gilead

$67.11

0.02 (0.03%)

14:51
12/09/19
12/09
14:51
12/09/19
14:51
Hot Stocks
Gilead's Kite says results ZUMA-2 trial support regulatory filings »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMDA

Gamida Cell

$5.10

0.01 (0.20%)

14:49
12/09/19
12/09
14:49
12/09/19
14:49
Hot Stocks
Gamida Cell announces results from Phase 1 clinical study of GDA-201 »

Gamida Cell announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFIX

Stitch Fix

$25.05

0.92 (3.81%)

14:49
12/09/19
12/09
14:49
12/09/19
14:49
Options
Stitch Fix options imply 24.0% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 11

    Dec

  • 12

    Dec

  • 19

    Dec

GILD

Gilead

$67.08

-0.01 (-0.01%)

14:47
12/09/19
12/09
14:47
12/09/19
14:47
Hot Stocks
Gilead's Kite announces findings from ongoing post-marketing study of Yescarta »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUAN

Nuance

$17.55

-0.34 (-1.90%)

14:45
12/09/19
12/09
14:45
12/09/19
14:45
Options
Nuance call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

GS

Goldman Sachs

$222.17

-2.4 (-1.07%)

, SFTBF

SoftBank

$0.00

(0.00%)

14:41
12/09/19
12/09
14:41
12/09/19
14:41
Periodicals
SoftBank taps Goldman for $1.75B financing to help revive WeWork, Bloomberg says »

SoftBank (SFTBF) has…

GS

Goldman Sachs

$222.17

-2.4 (-1.07%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

  • 26

    Feb

CBL

CBL & Associates

$1.12

-0.025 (-2.18%)

14:36
12/09/19
12/09
14:36
12/09/19
14:36
Hot Stocks
CBL & Associates closes sale of interest in the Outlet Shoppes at Atlanta »

CBL Properties announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

14:25
12/09/19
12/09
14:25
12/09/19
14:25
Options
Berkshire Hathaway call volume above normal and directionally bullish »

Bullish option flow…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
12/09/19
12/09
14:17
12/09/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
12/09/19
12/09
14:16
12/09/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.